Logo image of VTYX

VENTYX BIOSCIENCES INC (VTYX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VTYX - US92332V1070 - Common Stock

9.03 USD
+0.28 (+3.2%)
Last: 12/31/2025, 8:00:02 PM
9.03 USD
0 (0%)
After Hours: 12/31/2025, 8:00:02 PM
Fundamental Rating

3

VTYX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for VTYX as it has an excellent financial health rating, but there are worries on the profitability. VTYX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year VTYX has reported negative net income.
In the past year VTYX has reported a negative cash flow from operations.
VTYX had negative earnings in each of the past 5 years.
VTYX had a negative operating cash flow in each of the past 5 years.
VTYX Yearly Net Income VS EBIT VS OCF VS FCFVTYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

VTYX has a worse Return On Assets (-50.41%) than 61.78% of its industry peers.
With a Return On Equity value of -55.71%, VTYX perfoms like the industry average, outperforming 50.79% of the companies in the same industry.
Industry RankSector Rank
ROA -50.41%
ROE -55.71%
ROIC N/A
ROA(3y)-49.18%
ROA(5y)-2852.36%
ROE(3y)-54.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VTYX Yearly ROA, ROE, ROICVTYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VTYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTYX Yearly Profit, Operating, Gross MarginsVTYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

8

2. Health

2.1 Basic Checks

VTYX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VTYX has more shares outstanding
There is no outstanding debt for VTYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VTYX Yearly Shares OutstandingVTYX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
VTYX Yearly Total Debt VS Total AssetsVTYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

VTYX has an Altman-Z score of 14.31. This indicates that VTYX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 14.31, VTYX belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
VTYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.31
ROIC/WACCN/A
WACCN/A
VTYX Yearly LT Debt VS Equity VS FCFVTYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

VTYX has a Current Ratio of 17.86. This indicates that VTYX is financially healthy and has no problem in meeting its short term obligations.
VTYX has a Current ratio of 17.86. This is amongst the best in the industry. VTYX outperforms 88.48% of its industry peers.
VTYX has a Quick Ratio of 17.86. This indicates that VTYX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 17.86, VTYX belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.86
Quick Ratio 17.86
VTYX Yearly Current Assets VS Current LiabilitesVTYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.44% over the past year.
EPS 1Y (TTM)36.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VTYX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.18% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.43%
EPS Next 2Y6.36%
EPS Next 3Y0.98%
EPS Next 5Y10.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VTYX Yearly Revenue VS EstimatesVTYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
VTYX Yearly EPS VS EstimatesVTYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

0

4. Valuation

4.1 Price/Earnings Ratio

VTYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTYX Price Earnings VS Forward Price EarningsVTYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTYX Per share dataVTYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.36%
EPS Next 3Y0.98%

0

5. Dividend

5.1 Amount

No dividends for VTYX!.
Industry RankSector Rank
Dividend Yield 0%

VENTYX BIOSCIENCES INC

NASDAQ:VTYX (12/31/2025, 8:00:02 PM)

After market: 9.03 0 (0%)

9.03

+0.28 (+3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-04 2026-02-04/amc
Inst Owners68.47%
Inst Owner Change-1.58%
Ins Owners4.11%
Ins Owner Change0.61%
Market Cap644.38M
Revenue(TTM)N/A
Net Income(TTM)-106.61M
Analysts82.67
Price Target14.92 (65.23%)
Short Float %8.9%
Short Ratio1.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.41%
Min EPS beat(2)20.73%
Max EPS beat(2)30.09%
EPS beat(4)4
Avg EPS beat(4)24.4%
Min EPS beat(4)20.73%
Max EPS beat(4)30.09%
EPS beat(8)8
Avg EPS beat(8)19.04%
EPS beat(12)9
Avg EPS beat(12)10.5%
EPS beat(16)12
Avg EPS beat(16)11.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.64%
PT rev (3m)32.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.86%
EPS NY rev (1m)13%
EPS NY rev (3m)13.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.37
P/tB 3.37
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.72
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS2.68
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.41%
ROE -55.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.18%
ROA(5y)-2852.36%
ROE(3y)-54.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -20.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.86
Quick Ratio 17.86
Altman-Z 14.31
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)216.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y25.43%
EPS Next 2Y6.36%
EPS Next 3Y0.98%
EPS Next 5Y10.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.18%
EBIT Next 3Y9.01%
EBIT Next 5YN/A
FCF growth 1Y45.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.88%
OCF growth 3YN/A
OCF growth 5YN/A

VENTYX BIOSCIENCES INC / VTYX FAQ

What is the ChartMill fundamental rating of VENTYX BIOSCIENCES INC (VTYX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VTYX.


What is the valuation status for VTYX stock?

ChartMill assigns a valuation rating of 0 / 10 to VENTYX BIOSCIENCES INC (VTYX). This can be considered as Overvalued.


How profitable is VENTYX BIOSCIENCES INC (VTYX) stock?

VENTYX BIOSCIENCES INC (VTYX) has a profitability rating of 0 / 10.


How financially healthy is VENTYX BIOSCIENCES INC?

The financial health rating of VENTYX BIOSCIENCES INC (VTYX) is 8 / 10.